<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitrofurantoin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitrofurantoin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitrofurantoin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9704" href="/d/html/9704.html" rel="external">see "Nitrofurantoin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10912" href="/d/html/10912.html" rel="external">see "Nitrofurantoin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F202007"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Macrobid;</li>
<li>Macrodantin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397452"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Auro-Nitrofurantoin;</li>
<li>Macrobid [DSC];</li>
<li>PMS-Nitrofurantoin BID;</li>
<li>TEVA-Nitrofurantoin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048970"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F202031"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Oral suspension products are available in 2 concentrations (25 mg/5 mL [5 mg/mL] and 50 mg/5 mL [10 mg/mL]); verify product selection and avoid confusion between the different concentrations; dose should be clearly presented as "<b>mg</b>" instead of "mL."</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68ea4564-c2b6-429c-8a8b-e8846ecb9178">Urinary tract infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (UTI), treatment: Note:</b> Reserve for cystitis; should not be used for pyelonephritis or to treat febrile infants with UTI because renal and serum concentrations may not be adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-29292282','lexi-content-ref-34860955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-29292282','lexi-content-ref-34860955'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Furadantin, Macrodantin:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight-directed dosing</i>: Infants, Children, and Adolescents: Oral: 5 to 7 mg/kg/day divided every 6 hours for 7 days; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fixed dosing</i>: Infants, Children, and Adolescents: Furadantin oral suspension:</p>
<p style="text-indent:-2em;margin-left:8em;">≤4 kg: Oral: 5 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;4 to 5 kg: Oral: 7 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;5 to 7 kg: Oral: 9 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;7 to 10 kg: Oral: 12.5 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;10 to 14 kg: Oral: 17.5 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;14 to 20 kg: Oral: 25 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;20 to 25 kg: Oral: 35 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;25 to 30 kg: Oral: 42.5 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 to 40 kg: Oral: 50 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: Oral: 50 to 100 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Macrobid (macrocrystal/monohydrate): Adolescents: Oral: 100 mg every 12 hours for 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b887c7a-255f-4ba6-9db6-bbcbd2dc543e">Urinary tract infection, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, prophylaxis:</b> Furadantin, Macrodantin: Infants, Children, and Adolescents: Oral: 1 to 2 mg/kg/day in a single dose (at bedtime) or divided twice daily; maximum daily dose: 100 mg/<b>day</b>. <b>Note:</b> In infants and children &lt;24 months, prophylaxis should only be considered for those with grade III or V reflux or with recurrent febrile UTI; data supporting the routine use of continuous antimicrobial prophylaxis are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940735','lexi-content-ref-21873694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940735','lexi-content-ref-21873694'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131218"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; based on experience in adults, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;60 mL/minute: Use is contraindicated per the manufacturer's labeling. In adults, limited data suggest nitrofurantoin is safe and effective for short-term treatment of uncomplicated acute cystitis in patients with an eGFR or CrCl 30 to 60 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31054588','lexi-content-ref-28155015','lexi-content-ref-23341159','lexi-content-ref-27100576','lexi-content-ref-25918178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31054588','lexi-content-ref-28155015','lexi-content-ref-23341159','lexi-content-ref-27100576','lexi-content-ref-25918178'])">Ref</a></span>). One retrospective cohort study reported increased risk of pulmonary adverse events in adult females with eGFR &lt;50 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23660771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23660771'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Use is contraindicated (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Based on adult information, avoid use (likely to be ineffective) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Based on adult information, avoid use (likely to be ineffective) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51131219"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling. Contraindicated in patients with a previous history of cholestatic jaundice or hepatic dysfunction associated with nitrofurantoin.</p></div>
<div class="block doa drugH1Div" id="F202012"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9704" href="/d/html/9704.html" rel="external">see "Nitrofurantoin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Dosage form information: </b>Nitrofurantoin is available in the United States as a combination product (nitrofurantoin monohydrate and nitrofurantoin macrocrystals [Macrobid]), which is typically dosed twice daily for the treatment of acute infections, <b>and</b> a preparation that consists solely of nitrofurantoin macrocrystals (oral suspension, Macrodantin), which is typically dosed 4 times daily for the treatment of acute infections. Regardless of the formulation used, advise patients to administer with food to improve absorption.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab9d68e1-55e9-4dfc-9dd3-caf70e5d3bae">Asymptomatic bacteriuria in pregnancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asymptomatic bacteriuria (≥10<sup>5</sup> CFU per mL) in pregnancy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although contraindicated by the manufacturer in pregnant patients at term (38 to 42 weeks' gestation), during labor and delivery, or when the onset of labor is imminent due to the possibility of hemolytic anemia in the newborn, the American College of Obstetricians and Gynecologists does not restrict use of nitrofurantoin during the third trimester. Based on available safety data, nitrofurantoin may also be used as an alternative therapy during the first trimester (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37473414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37473414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Nitrofurantoin monohydrate/macrocrystals (Macrobid): <b>Oral:</b> 100 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37473414','lexi-content-ref-30895288','lexi-content-ref-26255208','lexi-content-ref-19155904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37473414','lexi-content-ref-30895288','lexi-content-ref-26255208','lexi-content-ref-19155904'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1a4220f-46c7-4a95-9916-f259f6f99616">Cystitis, acute uncomplicated or acute simple cystitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection), treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider use of a different empiric agent in patients with suspected pyelonephritis, patients who have received nitrofurantoin in the last 3 months, or patients who have had a urine isolate with documented resistance to nitrofurantoin in the last 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-Hooton.2018a','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-Hooton.2018a','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Nitrofurantoin monohydrate/macrocrystals (Macrobid): <b>Oral:</b> 100 mg twice daily; treat females for 5 days and males for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17998493','lexi-content-ref-Gupta.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17998493','lexi-content-ref-Gupta.1','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Nitrofurantoin macrocrystals (oral suspension, Macrodantin): <b>Oral:</b> 50 to 100 mg every 6 hours; treat females for 5 days and males for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17998493','lexi-content-ref-Gupta.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17998493','lexi-content-ref-Gupta.1','lexi-content-ref-21292654'])">Ref</a></span>). <b>Note:</b> The recommended duration of therapy with this formulation is based on the recommendation for the nitrofurantoin monohydrate/macrocrystal formulation as well as expert opinion.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e303dd2-5a1d-4a4b-875e-d104de3485a0">Cystitis, prophylaxis for recurrent infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystitis, prophylaxis for recurrent infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be considered in nonpregnant women with bothersome, frequently recurrent cystitis despite nonantimicrobial preventive measures. The optimal duration has not been established; duration ranges from 3 to 12 months, with periodic reassessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-Gupta.2','lexi-content-ref-27542332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-Gupta.2','lexi-content-ref-27542332'])">Ref</a></span>). Prolonged use (&gt;6 months) of nitrofurantoin has been associated with diffuse interstitial pneumonitis and/or pulmonary fibrosis, chronic hepatitis, and the development of neuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7435512','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7435512','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Nitrofurantoin monohydrate/macrocrystals (Macrobid) (off-label use): <b>Oral:</b> 100 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-15295362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-15295362'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Nitrofurantoin macrocrystals (oral suspension, Macrodantin): <b>Oral:</b> 50 to 100 mg once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postcoital prophylaxis (females with cystitis temporally related to sexual intercourse):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Nitrofurantoin monohydrate/macrocrystals (Macrobid) (off-label use): <b>Oral:</b> 100 mg as a single dose taken within 2 hours of sexual intercourse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-6682903','lexi-content-ref-15295362','lexi-content-ref-19445741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-6682903','lexi-content-ref-15295362','lexi-content-ref-19445741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Nitrofurantoin macrocrystals (oral suspension, Macrodantin): <b>Oral:</b> 50 to 100 mg as a single dose taken within 2 hours of sexual intercourse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-6682903','lexi-content-ref-19445741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-6682903','lexi-content-ref-19445741'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990825"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;60 mL/minute: Although contraindicated in the manufacturer's labeling, limited data suggest nitrofurantoin is safe and effective for short-term treatment of uncomplicated acute cystitis in patients with an eGFR or CrCl 30 to 60 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31054588','lexi-content-ref-28155015','lexi-content-ref-23341159','lexi-content-ref-27100576','lexi-content-ref-25918178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31054588','lexi-content-ref-28155015','lexi-content-ref-23341159','lexi-content-ref-27100576','lexi-content-ref-25918178'])">Ref</a></span>). One retrospective cohort study reported increased risk of pulmonary adverse events in patients with eGFR &lt;50 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23660771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23660771'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824','lexi-content-ref-28155015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824','lexi-content-ref-28155015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained low-efficiency diafiltration):</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988037"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Contraindicated in patients with a previous history of cholestatic jaundice or hepatic dysfunction associated with nitrofurantoin.</p></div>
<div class="block arsc drugH1Div" id="F55628901"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection has occurred with nitrofurantoin, including <b>
<i>Clostridioides difficile</i> associated diarrhea</b> and <b>
<i>Clostridioides difficile</i> colitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8277174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8277174'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospitalization or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors, H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced liver injury (DILI)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A wide range of drug-induced liver injury (DILI) has been reported with nitrofurantoin, including acute<b> hepatitis</b>, granulomatous reaction, <b>cholestatic jaundice</b>, <b>autoimmune hepatitis</b>, and <b>chronic active hepatitis</b> that may lead to <b>hepatic</b>
<b>cirrhosis</b> or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7435512','lexi-content-ref-22479069','lexi-content-ref-24926677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7435512','lexi-content-ref-22479069','lexi-content-ref-24926677'])">Ref</a></span>). Acute liver injury usually presents with a hepatocellular pattern with or without jaundice and is commonly associated with <b>fever</b> and <b>skin rash</b> and typically resolves with discontinuation. Chronic liver injury usually presents with autoimmune features and is associated with fatigue, weakness, dark urine, and jaundice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24926677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24926677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not clearly established; oxidative-free radicals may damage hepatocytes. An autoimmune mechanism may also contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24926677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24926677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; acute liver injury may vary in onset from 1 to 6 weeks of use and chronic liver injury may vary in onset from months (typically &gt;6 months) to years of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24926677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24926677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24926677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24926677'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24926677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24926677'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged use (&gt;6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24926677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24926677'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral neuropathy</b> may occur with nitrofurantoin and typically presents as sensorimotor polyneuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-888840','lexi-content-ref-17666646','lexi-content-ref-22332195','lexi-content-ref-6272676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-888840','lexi-content-ref-17666646','lexi-content-ref-22332195','lexi-content-ref-6272676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6282377','lexi-content-ref-22332195']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6282377','lexi-content-ref-22332195'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients</p>
<p style="text-indent:-2em;margin-left:6em;">• Anemia</p>
<p style="text-indent:-2em;margin-left:6em;">• Debilitating disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes</p>
<p style="text-indent:-2em;margin-left:6em;">• Electrolyte imbalance</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (CrCl &lt;60 mL/minute)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin B deficiency</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pulmonary toxicity may occur with nitrofurantoin and ranges from <b>acute pulmonary reaction</b>, <b>subacute pulmonary reaction</b>, and/or <b>chronic pulmonary reaction</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32953319','lexi-content-ref-7435512','lexi-content-ref-22479069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32953319','lexi-content-ref-7435512','lexi-content-ref-22479069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Acute reactions: Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32953319','lexi-content-ref-22479069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32953319','lexi-content-ref-22479069'])">Ref</a></span>). Chronic reactions: Unknown. May be T-cell mediated (non–dose-related) or direct toxicity (dose-related) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32238797','lexi-content-ref-22836745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32238797','lexi-content-ref-22836745'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; acute reactions can vary in onset from days to weeks while chronic reactions often occurs after months to years of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32953319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32953319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32953319','lexi-content-ref-7435512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32953319','lexi-content-ref-7435512'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32953319','lexi-content-ref-7435512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32953319','lexi-content-ref-7435512'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged use (&gt;6 months) (for chronic pulmonary reactions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32953319','lexi-content-ref-7435512','lexi-content-ref-27100576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32953319','lexi-content-ref-7435512','lexi-content-ref-27100576'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F201972"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum phosphate (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (2%), nausea (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (1% to 5%), eosinophilia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (1% to 5%), increased serum aspartate aminotransferase (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness, drowsiness, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute pulmonary reaction (including cough, dyspnea, dyspnea on exertion, pleural effusion, pleuritic chest pain, pulmonary infiltrates)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Respiratory: Chronic pulmonary reaction (including diffuse interstitial pneumonitis, pulmonary fibrosis), subacute pulmonary reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bundle branch block (Dibagh Gandorta 2017), ECG changes, nonspecific T wave on ECG, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczematous rash, erythema multiforme, exfoliative dermatitis, maculopapular rash, Stevens-Johnson syndrome (Davis 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, <i>Clostridioides difficile</i> associated diarrhea (Hirschhorn 1994), <i>Clostridioides difficile</i> colitis, pancreatitis (Mouallen 2003), sialadenitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Roberts 2005), aplastic anemia, glucose-6-phosphate dehydrogenase deficiency anemia, granulocytopenia, hemolytic anemia, leukopenia, megaloblastic anemia, methemoglobinemia, thrombocytopenia (Dibagh Gandorta 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (Sakaan 2014), cholestatic jaundice (Sakaan 2014), chronic active hepatitis (Sakaan 2014), hepatic cirrhosis (Sakaan 2014), hepatic necrosis (Sakaan 2014), hepatitis (acute) (Sakaan 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, bulging fontanel (infants), confusion, depression, idiopathic intracranial hypertension, peripheral neuropathy (Tan 2012), psychotic reaction, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lupus-like syndrome, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Nystagmus disorder, optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cyanosis</p></div>
<div class="block coi drugH1Div" id="F201988"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Anuria, oliguria, or significant impairment of renal function (creatinine clearance [CrCl] &lt;60 mL/minute or clinically significant elevated serum creatinine); previous history of cholestatic jaundice or hepatic dysfunction associated with prior nitrofurantoin use; hypersensitivity to drug or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The manufacturer's contraindication in patients with CrCl &lt;60 mL/minute has been challenged in the literature; limited data suggest that an alternative creatinine clearance threshold may be considered (Oplinger 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the possibility of hemolytic anemia caused by immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent; also contraindicated in neonates younger than 1 month of age.</p></div>
<div class="block war drugH1Div" id="F201969"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: Use caution in patients with G6PD deficiency; may be at increased risk for hemolytic anemia. Discontinue therapy if occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is contraindicated in patients with a history of nitrofurantoin associated cholestatic jaundice or hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Urinary nitrofurantoin concentrations are variable in patients with impaired renal function. Use with caution. The manufacturer contraindicates use in CrCl &lt;60 mL/minute; however, limited data suggest nitrofurantoin is safe and effective for short-term treatment of uncomplicated urinary tract infection (UTI) in patients with CrCl 30 to 60 mL/minute (Cuhna 2017; Oplinger 2013; Santos 2016; Singh 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Avoid long-term use in older adult patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use is contraindicated in children &lt;1 month of age (at increased risk for hemolytic anemia).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Pyelonephritis: Not indicated for the treatment of pyelonephritis or perinephric abscesses.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878565"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Nitrofurantoin should not be used to treat UTIs in febrile infants and young children; nitrofurantoin concentrates in the urine and does not reach therapeutic serum and possibly parenchymal concentrations making it ineffective to treat pyelonephritis or urosepsis (AAP 2011). </p></div>
<div class="block foc drugH1Div" id="F201981"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Macrobid: 100 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Macrodantin: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Macrodantin: 50 mg, 100 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/5 mL (230 mL, 240 mL); 50 mg/5 mL (60 mL)</p></div>
<div class="block geq drugH1Div" id="F201965"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F201990"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Macrobid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $7.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Macrodantin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $14.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $3.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $6.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Nitrofurantoin Macrocrystal Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $7.03 - $12.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.13 - $2.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $3.38 - $3.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Nitrofurantoin Monohyd Macro Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.77 - $6.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Nitrofurantoin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $3.18 - $14.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $56.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867702"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Macrobid: 100 mg [DSC] [contains corn starch, edetate (edta) calcium disodium, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg</p></div>
<div class="block admp drugH1Div" id="F52613433"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food to improve absorption and decrease adverse effects. Shake suspension well before use and administer using an oral dosing syringe. The monohydrate/macrocrystals capsules (twice-daily formulation [eg, Macrobid]) should not be opened; the macrocrystals capsules (4-times-daily formulation [eg, Macrodantin]) may be opened and the contents mixed with food or juice for immediate use (data on file from manufacturer).</p></div>
<div class="block adm drugH1Div" id="F201985"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals to improve absorption and decrease adverse effects; suspension may be mixed with water, milk, or fruit juice. Shake suspension well before use. The monohydrate/macrocrystals capsules (twice-daily formulation [Macrobid]) should not be opened; the macrocrystals capsules (4-times-daily formulation [Macrodantin]) may be opened and the contents mixed with food or juice for immediate use (data on file from manufacturer).</p></div>
<div class="block sts drugH1Div" id="F202001"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store at controlled room temperature, 15°C to 30°C (59°F to 86°F). Dispense in a tight container using a child-resistant closure.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Avoid exposure to strong light, which may darken the drug. It is stable when stored between 20°C and 25°C (68°F and 77°F). Protect from freezing. Dispense in glass amber bottles.</p></div>
<div class="block usep drugH1Div" id="F53568043"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment and long-term suppression (prevention) of urinary tract infection (UTI) caused by susceptible bacteria (Furadantin, Macrodantin: FDA approved in ages ≥1 month and adults); treatment of acute uncomplicated UTI caused by susceptible strains (Macrobid: FDA approved in ages &gt;12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F3245417"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound alike/look alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Macrobid may be confused with microK, Nitro-Bid.</p>
<p style="text-indent:-2em;margin-left:4em;">Nitrofurantoin may be confused with Neurontin, nitroglycerin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Nitrofurantoin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potential for pulmonary toxicity, hepatotoxicity and peripheral neuropathy, particularly when given long-term; safer alternatives exist. Avoid use in patients with a CrCl less than 30 mL/minute or for long-term suppressive therapy (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Nitrofurantoin, when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of hemolytic anemia (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299767"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F201974"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Trisilicate: May decrease the absorption of Nitrofurantoin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Norfloxacin: Nitrofurantoin may diminish the therapeutic effect of Norfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May diminish the therapeutic effect of Nitrofurantoin. Probenecid may increase the serum concentration of Nitrofurantoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F202002"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Nitrofurantoin serum concentrations may be increased if taken with food. Management: Administer with meals.</p></div>
<div class="block dic drugH1Div" id="F7285895"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with meals to improve absorption and decrease adverse effects.</p></div>
<div class="block rep_considerations drugH1Div" id="F54787844"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Nitrofurantoin in doses &gt;10 mg/kg/day may cause spermatogenic arrest and decrease sperm count. This was observed in some patients treated for 2 weeks; sperm counts returned to normal between 13 and 32 weeks after therapy was discontinued. Consider avoiding use in patients planning to father a child (Drobnis 2017).</p></div>
<div class="block pri drugH1Div" id="F201991"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nitrofurantoin crosses the placenta (Perry 1967).</p>
<p style="text-indent:0em;margin-top:2em;">Current studies evaluating maternal use of nitrofurantoin during pregnancy and the development of congenital anomalies have had mixed results (ACOG 2023; Crider 2009; Goldberg 2013; Goldberg 2015; Muanda 2017; Nordeng 2013). An increased risk of neonatal jaundice was observed following maternal nitrofurantoin use during the last 30 days of pregnancy (Nordeng 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of nitrofurantoin may be altered. Based on a study of 30 women administered nitrofurantoin prior to abortion, maternal serum concentrations of nitrofurantoin may be decreased and urine concentrations may be increased during pregnancy (Philipson 1979).</p>
<p style="text-indent:0em;margin-top:2em;">Urinary tract infections are associated with adverse pregnancy outcomes including preterm birth and delivery of low-birth-weight infants. Treatment with a targeted antibiotic is recommended when asymptomatic bacteriuria or acute cystitis are diagnosed. According to the manufacturer, nitrofurantoin is contraindicated in pregnant patients at term (38 to 42 weeks' gestation), during labor and delivery, or when the onset of labor is imminent due to the possibility of hemolytic anemia in the newborn. However, nitrofurantoin may be used for the treatment of asymptomatic bacteriuria and acute cystitis in pregnant patients when appropriate. Nitrofurantoin may be used in the first trimester when alternative antibiotics cannot be used and may be considered as a first-line antibiotic in the second and third trimesters. Avoid use in pregnant patients with G6PD deficiency (ACOG 2023).</p></div>
<div class="block mopp drugH1Div" id="F53568033"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of pulmonary reaction; signs of numbness or tingling of the extremities; periodic liver and renal function tests; CBC. Observe for change in bowel frequency.</p></div>
<div class="block pha drugH1Div" id="F201968"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or alter bacterial ribosomal proteins leading to inhibition of protein synthesis, aerobic energy metabolism, DNA, RNA, and cell wall synthesis. Nitrofurantoin is bactericidal in urine at therapeutic doses. The broad-based nature of this mode of action may explain the lack of acquired bacterial resistance to nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria.</p></div>
<div class="block phk drugH1Div" id="F201987"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; macrocrystalline form absorbed more slowly due to slower dissolution (causes less GI distress)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.8 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 60% to 90%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Body tissues (except plasma) metabolize 60% of drug to inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Increased with food by ~40%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 20 to 60 minutes; prolonged with renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Urine (~40%) and feces (small amounts) as metabolites and unchanged drug</p>
<p style="text-indent:-2em;margin-left:4em;">Macrocrystals: Urine (20% to 25% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51154902"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Nitrofurantoin accumulates in serum.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F201993"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Uvamin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Furadantina | Furadantina mc | Urodantina | Urofuran</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Furadantin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-nitrofurantoin | Arx nitrofurantoin | Furadantin | Macrodantin | Nitrofurantoin bnm | Ralodantin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Nft | Nintoin | Nintoin sr | Nitrobac | Nitrofur | Ofuran sr | Rantoin | Umactin | Uritro | Urobak | Urocure</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Furadantine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Orafuran</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hantina | Macrodantina | Nitrofen | Nitrofurantoina | Urogen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Urodin | Uvamin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Macrodantina | Macrosan | Nitrofurantoina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Nitrofurantion</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Macrodantina | Macrodantina infantil | Nitrofurantoina | Nitrofurantoina mk | Urfadyne</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Furantoin | Furolin | Nifurantin | Nitrofurantoin ratiopharm</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Ituran | Nifurantin | Nifuretten | Nitrofurantoin ratiopharm | Uro-tablinen</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Nitrofurantoin "DAK"</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Chemiofuran | Furantoina | Macrodantina | Nitrofurantoina | Nitrofurantoina mk | Nyvu retard | Urigen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Furextol | Ivumod | Macrodantina | Nitrofurantoina | Nitrofurantoina mk | Urantoin | Uribiol | Urimax f | Urodantina | Urorelax | Uvamin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Apo-nitrofurantoin | Furadonin | Nifurantin | Nitrofurantoiin ns | Nitrofurantoin dak | Piyeloseptyl</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Colifuran | Macrodantin | Macrofuran | Mepafuran | Uvamin | Uvamine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Furantoina | Furobactina</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Macrofuran | Macrotoin | Urofuran</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Furadantine | Furadoine | Microdoine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Berkfurin | Furadantin | Genfura | Macrobid | Nitrofurantoin bristol laboratories | Nitrofurantoin cox | Nitrofurn kent old | Urantoin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Furolin | Nitrotoin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-nitrofurantoin | Furadantin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ninur | Prevuro</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nitrofurantoin q pharma | Nitrofurantoina arena</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Centran | Macrofuran</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Macrobid | Macrodantin | Uro-tablinen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Macrodantin | Uvamin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bactofuran | Furadantin | Furakem | Furent | Hiftas | Infura | Martifur | Nftor | Nifleri | Nifnext | Niftas | Niftran | Nifty | Nifutin | Nitbid sr | Nitfur | Nitro | Nitro f | Nitrobact | Nitrobest | Nitrofem | Nitrofur | Nitrostar | Rezfuran | Saftoin | Troydantin | Uribid | Urifar | Urifast | Urinif | Uristream nf | Uritop | Utirantin | Utitroy | Utivax nf | Xonift</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Samafurantin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Furecis | Furil | Macrodantin | Neo furadantin | Nitrofurantoina mylan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Furolin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Uretoin azusa | Uretoin mitsubishi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Nifuran</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Boryung nitrofurantoin | Pricetin | Uroin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Uvamine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Nitrafuron | Uvamin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Furadonim | Furadonin | Furantoin | Orafuran | Urosept | Uvamin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Furadantine | Nitrofurantoin ratiopharm</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Furadonin | Furantoin | Orafuran | Urosept | Uvamin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Furadantine | Furadoine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anmic | Biofurin | Dutarina | Furadantina | Furitex | Futroken | Ircilus | Macrodantina | Macrodantina infantil | Macrofurin | Nitrofurantoina | Nitrofurantoina biomep | Nitrofurantoina bioresearch | Nitrofurantoina darier | Nitrofurantoina exakta | Nitrofurantoina farmadem | Nitrofurantoina loeffler | Nitrofurantoina ultra | Nitrofurantoina valeant | Suronit | Terfhicid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Nifurantin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">De shalom nitrofurantoin | Nitrofrat</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Furabid | Furadantine | Nitrofurantoin Aurobindo MC | Nitrofurantoine m.c.</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Furadantine | Furantoina | Nifurantin | Nitrofurantoine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Macrobid | Nifuran</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Apo-nitrofurantoin | Eraceplus | Infurin | Macrodantina | Nifurin | Nitrofurantoina | Urodantina | Urofurin | Urofurin xr | Urotoin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Macrodantin | Nitro | Nitromic | Norfuran | Urontin | Usa lab nitrofurantoin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anatrin | Furadantin | Furadin | Furalin | Furantin | Urifast</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Furantoin | Nifuratio | Siraliden</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Macrobid | Macrodantin | Nitrofurant macro | Nitrofurantoin | Nitrofurantoin (monohydrate/macrocrystals) | Nitrofurantoin macrocrystals | Nitrofurantoin Mono/Mac | Nitrofurantoin mono/macro | Nitrofurantoin monohydrate/macrocrystals</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Furadantina | Furocape | Nitrofurantoina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Urotoina | Urotoina pediatrica</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Colifuran | Piyeloseptyl | Uvamin Retard</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Furadonin | Furadonin avexima</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-nitrofurantoin | Colifuran</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Nitrofurantoin alternova</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-nitrofurantoin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Macrobid | Macrodantin | Ninur</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Furantoin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Macrodantin | Manopill</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Apo-nitrofurantoin | Furadantine | Furadoine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Piyeloseptyl | Urineks</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Frantin | Furadantin-Mc | Limicon | Litolin | Macrodantin | Nifutoin | Ninru | Nitoson | Nitrofurabtoin | Nitrofurantin | Tirin | Yumenin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Furadonin | Urosept | Uvamin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agotoin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Brandtoina | Furanpur | Macrofuran</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Furadina | Macrodantina | Nitrofur | Nitrofurantoina | Urodantina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Furadantin | Macrodantin | Nitrofurantoin cipla | Turanto | Unitro | Urantin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Kantibac</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Urantoin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28554926">
<a name="28554926"></a>Ahmed H, Davies F, Francis N, Farewell D, Butler C, Paranjothy S. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. <i>BMJ Open</i>. 2017;7(5):e015233. doi:10.1136/bmjopen-2016-015233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/28554926/pubmed" id="28554926" target="_blank">28554926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15266443">
<a name="15266443"></a>Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. <i>Cochrane Database Syst Rev</i>. 2004;(3):CD001209. doi:10.1002/14651858.CD001209.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/15266443/pubmed" id="15266443" target="_blank">15266443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27940735">
<a name="27940735"></a>American Academy of Pediatrics (AAP) Subcommittee on urinary tract infection. Reaffirmation of AAP Clinical Practice Guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2-24 months of age. <i>Pediatrics</i>. 2016;138(6).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27940735/pubmed" id="27940735" target="_blank">27940735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics (AAP). Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37473414">
<a name="37473414"></a>American College of Obstetricians and Gynecologists (ACOG). Urinary tract infections in pregnant individuals. <i>Obstet Gynecol</i>. 2023;142(2):435-445. doi:10.1097/AOG.0000000000005269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/37473414/pubmed" id="37473414" target="_blank">37473414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31042112">
<a name="31042112"></a>Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. <i>J Urol</i>. 2019;202(2):282-289. doi:10.1097/JU.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/31042112/pubmed" id="31042112" target="_blank">31042112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32953319">
<a name="32953319"></a>Batzlaff C, Koroscil M. Nitrofurantoin-induced pulmonary toxicity: always review the medication list. <i>Cureus</i>. 2020;12(8):e9807. doi:10.7759/cureus.9807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/32953319/pubmed" id="32953319" target="_blank">32953319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17495377">
<a name="17495377"></a>Bhullar S, Lele SM, Kraman S. Severe nitrofurantoin lung disease resolving without the use of steroids. <i>J Postgrad Med.</i> 2007;53(2):111-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/17495377/pubmed" id="17495377" target="_blank">17495377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-32. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>CDC. Clostridioides difficile FAQs for clinicians about <i>C. diff.</i> 2020. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32238797">
<a name="32238797"></a>Chin AJ, Rashid S, Gharibeh TR, Kibbe PS, Wynbrandt JH. Interstitial lung disease secondary to long-term nitrofurantoin use. <i>Am J Case Rep</i>. 2020;21:e920386. doi:10.12659/AJCR.920386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/32238797/pubmed" id="32238797" target="_blank">32238797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31054588">
<a name="31054588"></a>Chung C, Bouwmeester C. Nitrofurantoin use in frail, community-dwelling, older adults with renal impairment. <i>Sr Care Pharm</i>. 2019;34(5):303-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/31054588/pubmed" id="31054588" target="_blank">31054588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28155015">
<a name="28155015"></a>Cunha BA, Cunha CB, Lam B, et al. Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications. <i>Eur J Clin Microbiol Infect Dis</i>. 2017;36(7):1213-1216. doi:10.1007/s10096-017-2911-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/28155015/pubmed" id="28155015" target="_blank">28155015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30059372">
<a name="30059372"></a>Davis WD, Schafer PA. Stevens-Johnson syndrome: a challenging diagnosis. <i>Adv Emerg Nurs J</i>. 2018;40(3):176-182. doi:10.1097/TME.0000000000000197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/30059372/pubmed" id="30059372" target="_blank">30059372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29256130">
<a name="29256130"></a>Drobnis EZ, Nangia AK. Antimicrobials and male reproduction. <i>Adv Exp Med Biol.</i> 2017;1034:131-161. doi:10.1007/978-3-319-69535-8_10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/29256130/pubmed" id="29256130" target="_blank">29256130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873694">
<a name="21873694"></a>Finnell SM, Carroll AE, Downs SM, Subcommittee on Urinary Tract Infection. Technical report—diagnosis and management of an initial UTI in febrile infants and young children. <i>Pediatrics</i>. 2011;128(3):e749-e770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/21873694/pubmed" id="21873694" target="_blank">21873694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furadantin.1">
<a name="Furadantin.1"></a>Furadantin (nitrofurantoin) oral suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furadantin.2">
<a name="Furadantin.2"></a>Furadantin (nitrofurantoin) oral suspension [prescribing information]. East Brunswick, NJ: Casper Pharma LLC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28536210">
<a name="28536210"></a>Gandotra SD, Smotrys MA, Patel DB, Chadha A. Systemic inflammatory response syndrome (SIRS) and a left bundle branch block (LBBB) due to nitrofurantoin. <i>BMJ Case Rep</i>. 2017;2017:bcr2016218127. doi:10.1136/bcr-2016-218127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/28536210/pubmed" id="28536210" target="_blank">28536210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23660771">
<a name="23660771"></a>Geerts AF, Eppenga WL, Heerdink R, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. <i>Eur J Clin Pharmacol</i>. 2013;69(9):1701-1707. doi:10.1007/s00228-013-1520-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23660771/pubmed" id="23660771" target="_blank">23660771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11401180">
<a name="11401180"></a>Gerk PM, Kuhn RJ, Desai NS, McNamara PJ. Active transport of nitrofurantoin into human milk. <i>Pharmacotherapy</i>. 2001;21(6):669-675. doi:10.1592/phco.21.7.669.34574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/11401180/pubmed" id="11401180" target="_blank">11401180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23873250">
<a name="23873250"></a>Goldberg O, Koren G, Landau D, Lunenfeld E, Matok I, Levy A. Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations. <i>J Clin Pharmacol</i>. 2013;53(9):991-995. doi:10.1002/jcph.139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23873250/pubmed" id="23873250" target="_blank">23873250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25767948">
<a name="25767948"></a>Goldberg O, Moretti M, Levy A, Koren G. Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis. <i>J Obstet Gynaecol Can</i>. 2015;37(2):150-156. doi:10.1016/S1701-2163(15)30337-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/25767948/pubmed" id="25767948" target="_blank">25767948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.1">
<a name="Golightly.1"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. </i>Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2018a">
<a name="Hooton.2018a"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.2">
<a name="Gupta.2"></a>Gupta K. Recurrent simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17998493">
<a name="17998493"></a>Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. <i>Arch Intern Med.</i> 2007;167(20):2207-2212. doi:10.1001/archinte.167.20.2207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/17998493/pubmed" id="17998493" target="_blank">17998493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis.</i> 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8277174">
<a name="8277174"></a>Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. Epidemiology of community-acquired <i>Clostridium difficile</i>-associated diarrhea. <i>J Infect Dis</i>. 1994;169(1):127-133. doi:10.1093/infdis/169.1.127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/8277174/pubmed" id="8277174" target="_blank">8277174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7435512">
<a name="7435512"></a>Holmberg L, Boman G, Böttiger LE, Eriksson B, Spross R, Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. <i>Am J Med</i>. 1980;69(5):733-738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/7435512/pubmed" id="7435512" target="_blank">7435512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6072610">
<a name="6072610"></a>Hosbach RH, Foster RB. Absence of nitrofurantoin from human milk. <i>JAMA</i>. 1967;202(11):1057.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/6072610/pubmed" id="6072610" target="_blank">6072610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-888840">
<a name="888840"></a>Jacknowitz AI, Le Frock JL, Prince RA. Nitrofurantoin polyneuropathy: report of two cases. <i>Am J Hosp Pharm</i>. 1977;34(7):759-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/888840/pubmed" id="888840" target="_blank">888840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17666646">
<a name="17666646"></a>Kammire LD, Donofrio PD. Nitrofurantoin neuropathy: a forgotten adverse effect. <i>Obstet Gynecol</i>. 2007;110(2 Pt 2):510-512. doi:10.1097/01.AOG.0000267134.21517.41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/17666646/pubmed" id="17666646" target="_blank">17666646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26255208">
<a name="26255208"></a>Kazemier BM, Koningstein FN, Schneeberger C, et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. <i>Lancet Infect Dis</i>. 2015;15(11):1324-1333. doi:10.1016/S1473-3099(15)00070-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/26255208/pubmed" id="26255208" target="_blank">26255208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22479069">
<a name="22479069"></a>Kiang TK, Ford JA, Yoshida EM, Partovi N. Nitrofurantoin-associated lung and liver toxicity leading to liver transplantation in a middle-aged patient. <i>Can J Hosp Pharm</i>. 2011;64(4):262-270. doi:10.4212/cjhp.v64i4.1039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/22479069/pubmed" id="22479069" target="_blank">22479069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34860955">
<a name="34860955"></a>Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in pediatric patients. <i>J Pharm Technol</i>. 2018;34(2):62-81. doi:10.1177/8755122518755402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/34860955/pubmed" id="34860955" target="_blank">34860955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19155904">
<a name="19155904"></a>Lumbiganon P, Villar J, Laopaiboon M, et al; World Health Organization Asymptomatic Bacteriuria Trial Group. One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial. <i>Obstet Gynecol</i>. 2009;113(2, pt 1):339-345. doi:10.1097/AOG.0b013e318195c2a2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/19155904/pubmed" id="19155904" target="_blank">19155904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Macrobid.1">
<a name="Macrobid.1"></a>Macrobid (nitrofurantoin) [prescribing information]. Morristown, NJ: Almatica Pharma LLC; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Macrodantin.2">
<a name="Macrodantin.2"></a>Macrodantin (nitrofurantoin) [prescribing information]. Morristown, NJ: Almatica Pharma LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22836745">
<a name="22836745"></a>Madani Y, Mann B. Nitrofurantoin-induced lung disease and prophylaxis of urinary tract infections. <i>Prim Care Respir J</i>. 2012;21(3):337-341. doi:10.4104/pcrj.2012.00059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/22836745/pubmed" id="22836745" target="_blank">22836745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Microdantin.1">
<a name="Microdantin.1"></a>Microdantin (nitrofurantoin) [prescribing information]. Morristown, NJ: Almatica Pharma Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14719480">
<a name="14719480"></a>Mouallem M, Sirotin T, Farfel Z. Nitrofurantoin-induced pancreatitis. <i>Isr Med Assoc J</i>. 2003;5(10):754-755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/14719480/pubmed" id="14719480" target="_blank">14719480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27542332">
<a name="27542332"></a>Muller AE, Verhaegh EM, Harbarth S, Mouton JW, Huttner A. Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials. <i>Clin Microbiol Infect</i>. 2017;23(6):355-362. doi:10.1016/j.cmi.2016.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27542332/pubmed" id="27542332" target="_blank">27542332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30895288">
<a name="30895288"></a>Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/30895288/pubmed" id="30895288" target="_blank">30895288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23344280">
<a name="23344280"></a>Nordeng H, Lupattelli A, Romøren M, et al. Neonatal outcomes after gestational exposure to nitrofurantoin. <i>Obstet Gynecol</i>. 2013;121(2, pt 1):306-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23344280/pubmed" id="23344280" target="_blank">23344280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitrofurantoin.2">
<a name="Nitrofurantoin.2"></a>Nitrofurantoin oral suspension [prescribing information]. East Brunswick, NJ: Rising Pharma Holdings, Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nitrofurantoin.1">
<a name="Nitrofurantoin.1"></a>Nitrofurantoin oral suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23341159">
<a name="23341159"></a>Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. <i>Ann Pharmacother</i>. 2013;47(1):106-111. doi:10.1345/aph.1R352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/23341159/pubmed" id="23341159" target="_blank">23341159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6282377">
<a name="6282377"></a>Penn RG, Griffin JP. Adverse reactions to nitrofurantoin in the United Kingdom, Sweden, and Holland. <i>Br Med J (Clin Res Ed)</i>. 1982;284(6327):1440-1442. doi:10.1136/bmj.284.6327.1440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/6282377/pubmed" id="6282377" target="_blank">6282377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6068160">
<a name="6068160"></a>Perry JE, Leblanc AL. Transfer of nitrofurantoin across the human placenta. <i>Tex Rep Biol Med.</i> 1967a;25(2):265-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/6068160/pubmed" id="6068160" target="_blank">6068160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6682903">
<a name="6682903"></a>Pfau A, Sacks T, Engelstein D. Recurrent urinary tract infections in premenopausal women: prophylaxis based on an understanding of the pathogenesis. <i>J Urol</i>. 1983;129(6):1153-1157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/6682903/pubmed" id="6682903" target="_blank">6682903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-385210">
<a name="385210"></a>Philipson A. Pharmacokinetics of antibiotics in pregnancy and labour. <i>Clin Pharmacokinet</i>. 1979;4(4):297-309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/385210/pubmed" id="385210" target="_blank">385210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2364853">
<a name="2364853"></a>Pons G, Rey E, Richard MO, et al. Nitrofurantoin excretion in human milk. <i>Dev Pharmacol Ther</i>. 1990;14(3):148-152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/2364853/pubmed" id="2364853" target="_blank">2364853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15572603">
<a name="15572603"></a>Roberts AD, Neelamegam M. Agranulocytosis associated with nitrofurantoin therapy. <i>Ann Pharmacother</i>. 2005;39(1):198. doi:10.1345/aph.1E022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/15572603/pubmed" id="15572603" target="_blank">15572603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295362">
<a name="15295362"></a>Rogers RG, Kammerer-Doak D, Olsen A, et al. A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. <i>Am J Obstet Gynecol</i>. 2004;191(1):182-187. doi:10.1016/j.ajog.2004.03.088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/15295362/pubmed" id="15295362" target="_blank">15295362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24926677">
<a name="24926677"></a>Sakaan SA, Twilla JD, Usery JB, Winton JC, Self TH. Nitrofurantoin-induced hepatotoxicity: a rare yet serious complication. <i>South Med J</i>. 2014;107(2):107-113. doi:10.1097/SMJ.0000000000000059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/24926677/pubmed" id="24926677" target="_blank">24926677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27100576">
<a name="27100576"></a>Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the risk of nitrofurantoin lung injury and its efficacy in diminished kidney function in older adults in a large integrated healthcare system: a matched cohort study. <i>J Am Ger Soc.</i> 2016;64(4):798-805. doi:10.1111/jgs.14072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27100576/pubmed" id="27100576" target="_blank">27100576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19445741">
<a name="19445741"></a>Sen A. Recurrent cystitis in non-pregnant women [published online July 17, 2008]. <i>BMJ Clin Evid</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/19445741/pubmed" id="19445741" target="_blank">19445741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25918178">
<a name="25918178"></a>Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. <i>Can Med Assoc J. </i>2015;87(9):648-656. doi:10.1503/cmaj.150067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/25918178/pubmed" id="25918178" target="_blank">25918178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332195">
<a name="22332195"></a>Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC. Peripheral nerve toxic effects of nitrofurantoin. <i>Arch Neurol</i>. 2012;69(2):265-268. doi:10.1001/archneurol.2011.1120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/22332195/pubmed" id="22332195" target="_blank">22332195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4735457">
<a name="4735457"></a>Varsano I, Fischl J, Shochet SB. The excretion of orally ingested nitrofurantoin in human milk. <i>J Pediatr.</i> 1973;82(5):886-887. doi:10.1016/s0022-3476(73)80090-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/4735457/pubmed" id="4735457" target="_blank">4735457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6272676">
<a name="6272676"></a>Yiannikas C, Pollard JD, McLeod JG. Nitrofurantoin neuropathy. <i>Aust N Z J Med</i>. 1981;11(4):400-405. doi:10.1111/j.1445-5994.1981.tb03521.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/6272676/pubmed" id="6272676" target="_blank">6272676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24925943">
<a name="24925943"></a>Zao J, Koren G, Bozzo P. Using nitrofurantoin while breastfeeding a newborn. <i>Can Fam Physician</i>. 2014;60(6):539-540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrofurantoin-pediatric-drug-information/abstract-text/24925943/pubmed" id="24925943" target="_blank">24925943</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12645 Version 568.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
